ERK1/2 Signaling in Intrahepatic Cholangiocarcinoma: From Preclinical Advances to Therapeutic Strategies
Biology · 27.06.2025 · 14 (7) · 776
DOI: 10.3390/biology14070776 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biology, online erschienen am 27.06.2025. Verfasst von Veronica Porreca und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMMF-The Cholangiocarcinoma Charity, European Union - NextGenerationEU - PRIN 2022, Sapienza University of Rome-Fondi di Ateneo.
Abstract (Originalsprache)
Extracellular signal-regulated kinase 1/2 (ERK1/2) is involved in the regulation of the key cellular processes that are essential for the proper functioning of the cell under physiological conditions. Notably, the hyperactivation of ERK1/2 is implicated in oncogenesis and metastatic dissemination across various tumor types, making it an attractive candidate for targeted therapy (TT) through functional inhibition. In intrahepatic cholangiocarcinoma (iCCA), sustained ERK1/2 activation represents one of the major events within the complex signaling network that drives tumor development and progression. In this review, we dissect the biological role of ERK1/2 signaling in iCCA and highlight recent preclinical advances involving selective small-molecule ERK1/2 inhibitors. In vitro and in vivo studies have demonstrated how these inhibitors present effective anti-tumorigenic properties. In particular, PD901 and U0126 effectively reduce iCCA cell proliferation and invasion. Furthermore, Ulixertinib has shown a favorable therapeutic index and encouraging activity in clinical trials involving advanced solid tumors, including iCCA, paving the way for a new therapeutic approach targeting ERK1/2. Nevertheless, the heterogeneous and dynamic molecular landscape of iCCA, often accompanied by drug resistance, presents significant therapeutic challenges. We underscore how targeting the ERK1/2 pathway could represent a cornerstone within a multifaceted therapeutic strategy, fostering the development of personalized treatment approaches and improving clinical outcomes in iCCA patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
- Department of Biochemical Science, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
ORCID-Profile: Veronica Porreca, Giuseppina Mignogna, Carmine Mancone
Förderung
- AMMF-The Cholangiocarcinoma Charity
- European Union - NextGenerationEU - PRIN 2022
- Sapienza University of Rome-Fondi di Ateneo
- AMMF—The Cholangiocarcinoma Charity
- European Union—NextGenerationEU-PRIN
- Sa-pienza University of Rome—Fondi di Ateneo
Zitieren
APA
Porreca, V., Sallustio, L., Giancola, L., Angelone, P., Mignogna, G., Maras, B., & Mancone, C. (2025). ERK1/2 Signaling in Intrahepatic Cholangiocarcinoma: From Preclinical Advances to Therapeutic Strategies. Biology, 14(7), 776. https://doi.org/10.3390/biology14070776
Vancouver
Porreca V, Sallustio L, Giancola L, Angelone P, Mignogna G, Maras B, et al. ERK1/2 Signaling in Intrahepatic Cholangiocarcinoma: From Preclinical Advances to Therapeutic Strategies. Biology. 2025;14(7):776. doi:10.3390/biology14070776
BibTeX
@article{Porreca2025,
author = {Porreca, Veronica and Sallustio, Luca and Giancola, Ludovica and Angelone, Pietro and Mignogna, Giuseppina and Maras, Bruno and Mancone, Carmine},
title = {ERK1/2 Signaling in Intrahepatic Cholangiocarcinoma: From Preclinical Advances to Therapeutic Strategies},
journal = {Biology},
year = {2025},
volume = {14},
number = {7},
pages = {776},
doi = {10.3390/biology14070776}
}
EUVIMED